Andere Sprachen Antibe Therapeutics Inc.

Aktien

A2QJPN

CA0370255097

ATE

Markt geschlossen - Toronto S.E. Andere Börsenplätze 17:00:00 16.04.2024			% 5 Tage	% 1. Jan.
0,295 ^CAD	0,00 %		0,00 %	-68,28 %

09.04.	Antibe Therapeutics Inc. gibt Rücktritt vom Verwaltungsrat bekannt	CI
01.04.	Antibe Therapeutics Inc. gibt bekannt, dass die FDA Otenaproxesul klinisch zurückhält	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares	16.04.
Antibe Therapeutics Brief: Announcing TSX Delisting Review	16.04.
Antibe Announces TSX Delisting Review	16.04.
ANTIBE TO FILE AN APPLICATION FOR AN INITIAL ORDER UNDER COMPANIES CREDITORS ARRANGEMENT ACT	10.04.
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act	10.04.
DELETED: Canadian Investment Regulatory Organization Trade Resumption - ATE	09.04.
Canadian Investment Regulatory Organization Trading Halt - ATE	09.04.
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act	09.04.
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act	09.04.
Antibe Therapeutics Inc. Announces Board Resignations	09.04.
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order	01.04.
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator	01.04.
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01.04.
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01.04.
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01.04.
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01.04.
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul	01.04.
Antibe Therapeutics Inc. Announces Formation of Executive Committee	01.04.
Antibe Therapeutics Brief: Says to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting	20.03.
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting	20.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Antibe Therapeutics Inc.

Aktien

A2QJPN

CA0370255097

ATE

Andere Sprachen

Filter